How to buy Capricor Therapeutics stock | $3.86

Capricor Therapeutics, Inc is a biotechnology business based in the US. Capricor Therapeutics shares (CAPR) are listed on the NASDAQ and all prices are listed in US Dollars. Capricor Therapeutics employs 26 staff and has a trailing 12-month revenue of around 0.00.

Capricor Therapeutics stock price (NASDAQ: CAPR)

Use our graph to track the performance of CAPR stocks over time.

Capricor Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-29.

Latest market close	$3.86
52-week range	$3.13 - $8.82
50-day moving average	$4.89
200-day moving average	$4.99
Wall St. target price	$10.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-3.74

Buy Capricor Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Capricor Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Capricor Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Capricor Therapeutics price performance over time

Historical closes compared with the close of $3.86 from 2021-06-04

1 week (2021-07-22)	N/A
1 month (2021-07-02)	-22.49%
3 months (2021-04-30)	-16.63%
6 months (2021-01-29)	N/A

1 year (2020-07-29)	N/A
2 years (2019-07-29)	N/A
3 years (2018-07-29)	N/A
5 years (2016-07-29)	N/A

Capricor Therapeutics financials

Revenue TTM	$165,373
Gross profit TTM	$-8,146,750
Return on assets TTM	-36.19%
Return on equity TTM	-72.76%
Profit margin	0%
Book value	$1.60
Market capitalisation	$98.8 million

TTM: trailing 12 months

Shorting Capricor Therapeutics shares

There are currently 2.1 million Capricor Therapeutics shares held short by investors – that's known as Capricor Therapeutics's "short interest". This figure is 5.1% down from 2.3 million last month.

There are a few different ways that this level of interest in shorting Capricor Therapeutics shares can be evaluated.

Capricor Therapeutics's "short interest ratio" (SIR)

Capricor Therapeutics's "short interest ratio" (SIR) is the quantity of Capricor Therapeutics shares currently shorted divided by the average quantity of Capricor Therapeutics shares traded daily (recently around 656738.83792049). Capricor Therapeutics's SIR currently stands at 3.27. In other words for every 100,000 Capricor Therapeutics shares traded daily on the market, roughly 3270 shares are currently held short.

However Capricor Therapeutics's short interest can also be evaluated against the total number of Capricor Therapeutics shares, or, against the total number of tradable Capricor Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Capricor Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Capricor Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.1055% of the tradable shares (for every 100,000 tradable Capricor Therapeutics shares, roughly 106 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Capricor Therapeutics.

Find out more about how you can short Capricor Therapeutics stock.

Capricor Therapeutics share dividends

We're not expecting Capricor Therapeutics to pay a dividend over the next 12 months.

Have Capricor Therapeutics's shares ever split?

Capricor Therapeutics's shares were split on a 1:10 basis on 4 June 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Capricor Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Capricor Therapeutics shares which in turn could have impacted Capricor Therapeutics's share price.

Capricor Therapeutics share price volatility

Over the last 12 months, Capricor Therapeutics's shares have ranged in value from as little as $3.13 up to $8.82. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Capricor Therapeutics's is 6.5087. This would suggest that Capricor Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Capricor Therapeutics overview

Capricor Therapeutics, Inc. , a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.

Frequently asked questions

What percentage of Capricor Therapeutics is owned by insiders or institutions?
Currently 2.258% of Capricor Therapeutics shares are held by insiders and 19.059% by institutions. How many people work for Capricor Therapeutics?
Latest data suggests 26 work at Capricor Therapeutics. When does the fiscal year end for Capricor Therapeutics?
Capricor Therapeutics's fiscal year ends in December. Where is Capricor Therapeutics based?
Capricor Therapeutics's address is: 8840 Wilshire Boulevard, Beverly Hills, CA, United States, 90211 What is Capricor Therapeutics's ISIN number?
Capricor Therapeutics's international securities identification number is: US14070B3096 What is Capricor Therapeutics's CUSIP number?
Capricor Therapeutics's Committee on Uniform Securities Identification Procedures number is: 14070B101